With an eye on COVID-19 variants, University of Toronto, Sinai Health researchers design next-gen sequencing platform
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Two hours 200,000 calls 5,000 COVID-19 vaccinations booked
owensoundsuntimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from owensoundsuntimes.com Daily Mail and Mail on Sunday newspapers.
Knight Therapeutics Inc. a pan-American specialty pharmaceutical company, announced today the Canadian commercial availability of IBSRELA a first-in-class therapy for the treatment of irritable bowel syndrome with constipation in adults. Knight has the exclusive right to commercialize IBSRELA in Canada under the terms of a license agreement entered into with Ardelyx, Inc. in March 2018, which license agreement also …
Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today the Canadian commercial availability of IBSRELA (tenapanor), a first-in-class therapy for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Knight has the exclusive right to commercialize IBSRELA in Canada under the terms of a license agreement entered into with Ardelyx, Inc. (NASDAQ: ARDX) in March 2018, which license agreement also provides Knight with exclusive rights to commercialize tenapanor for hyperphosphate